Effects of extended lamivudine therapy in asian patients with chronic hepatitis B

Gastroenterology

Volumn 119, Issue 1, 2000, Pages 172-180

  Liaw, Yun Fan ^a   Leung, Nancy W Y ^f   Chang, Ting Tsung ^b   Guan, Richard ^c   Tai, Dar In ^a   Ng, Keng Yeen ^d   Chien, Rong Nan ^a   Dent, Julie ^e   Roman, Lise ^e   Edmundson, Sally ^e   Lai, Ching Lung ^f  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^d SINGAPORE GENERAL HOSPITAL   (Singapore)

^e GLAXOSMITHKLINE   (United Kingdom)

^f Chang Gung Memorial Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; LAMIVUDINE;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALAISE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

EID: 0034235528     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2000.8559     Document Type: Article

References (20)

1. Davey S. State of the World's Vaccines and Immunization. Geneva: World Health Organisation. 1996:76-82.
2. Hoofnagle JH, Alter HJ. Chronic viral hepatitis. In: Vyas GN, Dienstag JL, Hoofnagle JH, eds. Viral Hepatitis and Liver Disease. New York: Grune & Stratton, 1984;97-113.
3. De Jongh FE, Jamssea HL, De Man RA, Hop WC, Schalm SW, Blankenstein MV. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630-1635.
4. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study. Hepatology 1988;8:493-496.
5. Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, Liaw YF. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997;145:1039-1047.
6. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1998;12:S294-S308.
7. Tyrrell DLJ, Mitchell MC, De Man RA, Schalm SW, Main J, Thomas HC, Fevery J, Nevens F, Beranek P, Vicary C. Phase II trial of lamivudine for chronic hepatitis B (abstr). Hepatology 1993;18:112A.
8. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661.
9. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Fevery J, DeMan RH, Thomas HC. Lamivudine therapy for chronic hepatitis B: Six month dose-ranging study. Gastroenterology 1997;113:1258-1263.
10. Lai CL, Chien RN, Leung N, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. Lamivudine therapy for chronic hepatitis B: A 12 month double-blind, placebo-controlled multicentre study. New Engl J Med 1998;339:61-68.
11. Nowak M, Bonhoeffer S, Hill A, Boehme R, Thomas H, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996;93:4398-4402.
12. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrell DLY, Brown N, Condreay LD. Identification and biologic characterisation of mutations in HBV resistant to lamivudine. Hepatology 1998;27:1670-1677.
13. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen positive chronic hepatitis B. A metaanalysis. Ann Intern Med 1993;119:312-323.
14. Lok ASF, Ghany MG, Watson G, Ayola B. Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. J Viral Hepat 1998;5:171-178.
15. Chien RN, Liaw YF, Atkins M, for Asian hepatitis lamivudine trial group. Pretherapy alanine aminotransferase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999;30:770-774.
16. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999;29:971-975.
17. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D. Long-term follow-up of HBeAg positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-1427.
18. Korenman J, Baker B, Waggoner J, Everhart JE, DiBisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991;114:629-634.
19. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998;27:628-633.
20. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-572.